SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Mutation A27L

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials

1 Phase I/II Clinical Trial for the Evaluation of the Interaction Between Chemotherapy and Immunotherapy in Melanoma Patients

This phase I/II study is directed at evaluating safety and immunogenicity of a melanoma peptide vaccine in combination or not with Dacarbazine administration in melanoma patients

NCT00559026 Melanoma Biological: Melan-A Other: Melan-A plus Dacarbazine
MeSH:Melanoma
HPO:Cutaneous melanoma Melanoma

injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. --- A27L ---

Primary Outcomes

Measure: Assessment of safety by evaluating local and systemic adverse reactions during the trial. Assessment of the vaccine-specific cellular immune responses

Time: one year

Secondary Outcomes

Measure: Assessment of relapse-free survival and overall survival calculated from the time of the first chemotherapy/vaccine injection. Evaluation by microarray analysis of the gene expression profiles of patients PBMC 24 h after DTIC administration.

Time: two years

HPO Nodes

HP:0012056: Cutaneous melanoma
Genes 15
MC1R NRAS ERCC3 XPC NRAS BAP1 CDKN2A MITF CDK4 CXCR4 POLH WRN CDKN2A BRAF HRAS
Protein Mutations 13
A27L D820Y G86R L858R P1446A T790M V600D V600E V600K V600M V600R Y822D Y823D
SNP 0